A drug called apitegromab may help preserve lean body mass during weight loss with tirzepatide, a GLP-1 receptor agonist, according to a phase 2 clinical trial published in Nature Medicine. The findings suggest that blocking ...
Jun 9, 2026
0
9
A new pill developed by the British pharmaceutical firm AstraZeneca appears to help people lose a similar amount of weight as other oral GLP-1 drugs, trial results showed Monday.
Jun 9, 2026
0
9
A study of more than 229,000 obese adults without diabetes in the United States has shown that weight loss drugs are associated with a decreased risk of obesity-related cancers. The research found that GLP-1 receptor agonists ...
Jun 7, 2026
0
11
GLP-1 receptor agonist drugs, used for the treatment of diabetes—and more recently, weight loss—are associated with a significantly lower long-term risk of knee replacement surgery as a result of osteoarthritis, finds an ...
Jun 2, 2026
0
7
You've probably heard of Ozempic or Wegovy. These are the injectable drugs that have become household names for weight loss and diabetes.
Jun 2, 2026
0
6
A News and Perspectives report on emerging pharmaceutical access models in the United States has been published in the Journal of Medical Internet Research. In "Affordable GLP-1? When Digital Platforms Meet Policy Reform", ...
Jun 1, 2026
0
4
Drugs such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) are transforming obesity treatment, but without affordable, healthy food and appropriate support, they could widen health inequalities in the UK, according ...
Jun 1, 2026
0
4
Tirzepatide is superior to intensified conventional care (ICC) for adults with early type 2 diabetes (T2D) uncontrolled with metformin, according to a study published online May 26 in the Annals of Internal Medicine.
May 27, 2026
0
3
Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc's medicines regulator said on Friday.
May 22, 2026
0
9
Tirzepatide GLP-1 medication is known to improve sleep apnea for people with both obstructive sleep apnea (OSA) and obesity, but not all patients benefit equally. Now, new research presented at the 2026 ATS International ...
May 19, 2026
0
9
